Hello Herpes Advocates, We’re happy you’re here. We believe part of the reason there have been no advances in treatment or prevention in 40 years is due to stigma and lack of activism. There has never been a centralized advocacy effort for HSV until now.
Getting started with Herpes Advocacy
Step 1: Know the facts so you can speak to them in your advocacy.
Step 2: Sign up for Herpes Cure Advocacy Monthly Meeting
Contact your elected representatives
Next, most important: Contact your elected representatives to ask them to prioritize Herpes cure, treatment and prevention. Especially important targets for HSV Advocacy are listed below.
A sample letter/email is here.
|US Senate||US House of Representatives|
|Senate Appropriations Committee|
Senate LHHS Subcommittee
Senate HELP Committee
|House Appropriations Committee|
House LHHS Subcommittee
Contact Other Stakeholders:
United States Preventative Services Task Force (USPTSF)
Why advocacy at USPSF? USPSTF establishes guidelines for medical screening in the United States. They currently recommend against screening for HSV. Learn more about them here.
|Dr. Karina W. Davidson USPSTF Committee Chairfirstname.lastname@example.org |
|Dr. Amanda Borsky |
Dissemination and Implementation Advisor
Agency for Healthcare and Research Quality
CDC: Department for Prevention of Sexually Transmitted Diseases
Why advocacy at CDC? The Center for Disease Control and prevention is responsible for prevention, surveillance, and establishes guidelines for testing and treatment for HSV in the United States. They currently recommend against screening for HSV. New STI treatment guidelines for HSV were published in 2021. Learn more about the CDC and their work here.
- Increase prevention efforts, outline a clear strategy to reduce transmission for HSV in the United States
- Increase training for new STI Treatment guidelines so that more people get tested (mild symptoms qualify someone for testing!)
- There is a critical public health need for a functional, accurate, diagnostic test to diagnose asymptomatic infection
|Dr. Jono Mermin|
Director of the National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)
|Dr. Leandro Mena, MD, MPH |
Director, Division of STD Prevention (DSTDP)
|Dr. Demetre Daskalakisemail@example.com|
Acting Deputy Director (DSTDP)
|Dr. Laura Bachmann|
Chief Medical Officer, DSTDP
Lead Public Health Policy Analyst , CDC
|STI Treatment Guidelines Commentsfirstname.lastname@example.org|
FDA Contacts and Committees
Why advocacy at FDA? The FDA reviews and approves new foods and medical products and provides regulatory oversight for businesses with products on market. The currently FDA-approved serologic antibody tests for diagnosing asymptomatic infection are wrong 50% of the time. Tell the FDA that we need higher standards for diagnostic tests! More background on the need for advocacy at the FDA is here.
|Patient Affairs Mailbox||Patientaffairs@fda.hhs.gov|
|Center for Biologics Evaluation and Research (CBER) Committee||CBERAdvisoryCommittees@fda.hhs.gov|
|Dr. Himani Bisht|
Assistant Director, Division of Microbiology and Devices
NIH: National Institute for Health: NIAID
Why advocacy at NIH? National Institutes of Health is responsible for research and development to bring new medical innovations to market in the United States. They fund both intra-curricular and extracurricular research through a robust grant program.
|Dr. Emily Erbelding|
Director of the NIAID Division of Microbiology and Infectious Diseases (DMID)
|Dr. Barbara Mulach |
Director, Office of Scientific Coordination and Program Operations, DMID
|Dr. Carolyn Deal |
STIs Section Chief
|Thomas Hiltke |
STIs Section Chief, STI Vaccines and Therapeutics Program Officer
|Dr. Jeffrey Cohen|
Chief, Laboratory of Infectious Diseases
Chief, Medical Virology Section
Other interest groups
ASHA, Chief Executive Officer
ASHA, Board President
|Black Maternal Health Caucus (US Congress)||BlackMaternalHealthCaucus@mail.house.gov|
Get in touch
Have a news tip? Are you working on clinical research for HSV treatments and want to share updates with the public? Let us know!
Never miss a thing. Sign up for emails.